ArticleBMC neurology2025
Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efgartigimod for Guillain-Barré syndrome: rationale, clinical evidence, and future perspectives.Frontiers in immunology · 2026Review
- Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management.ImmunoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGuillain-Barré syndrome (GBS) is a peripheral neuropathy mediated by immunoglobulin G (IgG) autoantibodies, which can cause acute flaccid paralysis. Miller-Fisher syndrome (MFS) is a variant of GBS, and in some cases, MFS may overlap with GBS (MFS-GBS overlap syndrome), potentially delaying the disease's progression. Apart from intravenous immunoglobulin (IVIg) and plasma exchange (PLEX), which are currently the clinical standard of care. However, at least 20-30% of patients develop acute respiratory failure during or shortly after IVIg or PLEX, and about 3-7% of patients die. Efgartigimod is an antagonist that targets the neonatal Fc receptor (FcRn) and shows promise in the treatment of GBS. CASE PRESENTATION: We present a case with MFS-GBS overlap syndrome who tested positive for serum ganglioside IgG antibodies. Despite completing a prescribed course of IVIg medication, the patient's symptoms continued to worsen, and she eventually developed respiratory failure. Subsequently, efgartigimod was used for treatment at a dose of 800 mg, administered four times in total. The patient's symptoms were relieved, leaving only external ophthalmoplegia. Additionally, using efgartigimod caused a gradual drop in the serum IgG level. This treatment regimen is the first reported.
conclusionFor MFS-GBS overlap syndrome patients with poor IVIg response, we discovered that sequential treatment with efgartigimod (800 mg, four doses) was safe, effective, and could reduce the course of the disease. Efgartigimod is anticipated to represent a significant advancement in treating GBS through ongoing, thorough basic and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.